Related Experiment Video

Updated: Jun 28, 2026

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

Targeting Src signaling in metastatic bone disease

John Araujo1, Christopher Logothetis

  • 1MD Anderson Cancer Center, Houston, TX 77030-3721, USA. johna@mdanderson.org

International Journal of Cancer
|October 23, 2008
PubMed

Insights

Src tyrosine kinase regulates cell growth and bone metabolism. Targeting Src may offer a new therapeutic strategy for cancers with bone metastases, addressing both tumor progression and skeletal destruction.

Area of Science:

  • Oncology
  • Cell Biology
  • Bone Metabolism

Background:

  • Src is a tyrosine kinase crucial for cellular functions like proliferation and survival.
  • Src plays a significant role in regulating bone metabolism.
  • Overexpression of Src is observed in various cancers, including breast, prostate, and lung tumors.

Purpose of the Study:

  • To explore the role of Src in cancer pathogenesis and bone metabolism.
  • To investigate Src signaling in the context of bone metastases.
  • To evaluate Src as a potential therapeutic target for bone metastases.

Main Methods:

  • Review of existing literature on Src function in cancer and bone.
  • Analysis of Src signaling pathways in tumor cells and bone cells.
  • Examination of the link between Src activity and osteoclast function.

Main Results:

  • Src is implicated in the progression of multiple cancer types.
  • Aberrant Src signaling contributes to increased osteoclastic activity in bone metastases.
  • Metastatic cells disrupt bone remodeling, creating a cycle of destruction.

Conclusions:

  • Src is a key regulator in both cancer development and bone metabolism.
  • Targeting Src may be a viable therapeutic approach for patients with bone metastases.
  • Inhibiting Src could potentially disrupt the cycle of metastatic bone destruction.

More Related Videos

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

Models of Bone Metastasis08:49

Models of Bone Metastasis

Published on: September 4, 2012

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...